穿心莲成分API 0134对高脂血症患者血小板膜糖蛋白表达的影响

作者	单位
王宏伟	华中科技大学同济医学院同济医院儿科
李树生	华中科技大学同济医学院同济医院儿科
王国平	华中科技大学同济医学院病理教研室
陶德定	华中科技大学同济医学院同济医院儿科
赵华月	华中科技大学同济医学院同济医院儿科

摘要点击次数: 1417

全文下载次数: 1557

中文摘要:

目的观察中药穿心莲成分API 0134(API)对高脂血症患者血小板膜糖蛋白的影响,探讨API抗血小板聚集的机制。方法随机选择30例高脂血症患者,应用免疫荧光标记和流式细胞仪测定静息血小板、活化血小板和不同浓度API作用后的活化血小板膜糖蛋白GPⅡb/Ⅲa、GPIb、P选择素(GMP-140)和血小板假性血友病因子(vWF)免疫荧光强度值。结果与活化血小板组比较,不同浓度API(25mg/L、50mg/L、100mg/L)均能够显著抑制GPⅡb/Ⅲa的平均荧光强度,抑制作用强度与用药剂量成正比;API 50mg/L和API 100mg/L亦能显著减低活化血小板的GMP-140,API 100mg/L可降低vWF的平均荧光强度(P<0.05,P<0.01)。不同浓度API对活化血小板膜糖蛋白GPIb表达影响不显著(P>0.05)。结论 API具有显著的抗血板GPⅡb/Ⅲa的药理作用,中、大剂量API对血小板GMP-140和vWF的表达亦有抑制作用。

英文摘要:

By observing the effect of API 0134, an active ingredient of green chiretta, on platelet membrane glycoprotein (GP) in patients with hyperlipemia to explore the mechanism of the anti-platelet aggregation effect of API. Methods The mean immunofluorescent intensity (MFI) of the platelet membrane glycoprotein GP Ⅱ b/Ⅲ a, GPIb, P-selectin (GMP-140) and von Willebrand’s factor (vWF) in resting platelet, activated platelet (untreated or treated with API 0134 of different concentrations) were detected in 30 randomly selected patients with hyperlipemia, using immunofluorescent marker and flow cytometry. Results API of all concentrations (25 mg/L, 50 mg/L and 100 mg/L) could significantly decrease the MFI of GP Ⅱ b/Ⅲ a in a positive dose-dependent manner, as compared with that in activated platelet untreated with API; API of 50 mg/L and 100 mg/L could also reduce the MFI of GMP-140 and vWF in activated platelet (P<0.01); but API of 100 mg/L showed insignificant influence on GPIb expression in activated platelet membrane. Conclusion API 0134 exerts obvious anti-platelet GP Ⅱ b/Ⅲ a effect on activated platelets, middle or large dose of API also shows inhibiting effect on GMP-140 and vWF expression in platelet.

关闭